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Summary Two multiple-dose studies were conducted in healthy post-menopausal female volunteers to
investigate the pharmacokinetics and effects on endocrinology of Arimidex (ZD1033). Volunteers in the first
trial were dosed with 3 mg of ZD1033 daily over 10 days to assess the effects on endocrinology of ZD1033 and
establish the pharmacokinetic profile. In the second trial volunteers received 14 daily doses of either 0.5 or
1.0 mg of ZD1033 to assess the pharmacokinetics of ZD1033 and the effects of low doses of ZD1033 on serum
oestradiol concentrations. Following multiple dosing a significant reduction in the concentration of serum
oestradiol of approximately 80% of baseline was obtained with all three doses; no recovery in oestradiol was
apparent for up to 144 h after the last dose. There was no overall difference in the level of oestradiol
suppression between the 0.5 or 1.0 mg doses of ZD1033. However, comparison of the number of volunteers
with oestradiol concentrations below the limits of detection of the assay, 24 h after the last dose of ZD1033,
suggested that 1.0 mg was the minimal dose required for maximal suppression of oestradiol. No significant
effect was recorded on serum concentrations of gonadotrophins over the dosing period. Serum concentrations
of a range of adrenal steroids were not affected by administration of ZD1033; furthermore, steroid response to
standard adrenocorticotrophic hormone (ACTH) challenge was unimpaired by ZD1033. Together these data
demonstrate the potency, tolerability and selectivity of ZD1033. The pharmacokinetic profile of ZD1033
supports its use as a once-daily treatment given orally.
Keywords: Arimidex; aromatase inhibitor; oestrogen
Breast cancer is the most common type of cancer in women,
accounting for 10% of all female cancers. It has been
estimated that in the year 2000 the worldwide incidence will
be between 1.1 and 1.4 million, whilst the mortality rate will
be approximately 500 000-700 000 (Miller et al., 1991).
Approximately one-third of human breast cancers are
oestrogen dependent and will regress following oestrogen
deprivation (Miller, 1989). In post-menopausal women the
major mechanism for oestrogen production is the peripheral
conversion (by aromatase) of the adrenal steroid androste-
nedione to oestrone and subsequently to oestradiol (Muss,
1992). Inhibition of aromatase therefore represents a
promising method of treatment for post-menopausal women
with breast cancer (Santen, 1991).
Aromatase inhibitors have been shown to be clinically
effective in the treatment of advanced breast cancer (Hoffken,
1993). However the most widely used commercially available
aromatase inhibitor, aminoglutethimide, is non-specific and
inhibits several enzymes responsible for adrenocorticosteroid
synthesis (Lonning and Johannessen, 1991). A second
aromatase inhibitor, formestane, is inconvenient to use since
it has to be given as a fortnightly intramuscular injection and
has been reported to lead to injection site reactions (Hoffken
et al., 1993).
Several new non-steroidal aromatase inhibitors such as
Arimidex (ZD1033) are currently undergoing clinical evalua-
tion because they offer advantages over current aromatase
inhibitors. ZD1033 is an achiral benzyltriazole derivative,
2,2[5-(1H-12,4-triazol-I-ylmethyl)-1,3-phenylene] bis (2-
methyl-propriononitrile) (Figure 1).
Preclinical studies have shown that ZD1033 is a highly
selective, potent aromatase inhibitor (Plourde et al., 1994).
ZD1033 is currently being evaluated in identical phase III
efficacy and tolerability studies vs megestrol acetate in post-
menopausal women with advanced breast cancer in the USA
and Europe.
This paper describes two studies that investigated the
pharmacokinetic profile, selectivity, tolerability and efficacy in
oestradiol suppression of multiple doses of ZD1033. The
objective of the studies was to determine the minimum dose
required for maximal suppression of circulating oestradiol,
while retaining selectivity for the aromatase enzyme. The
results of these studies were used as a basis for dose selection
for the phase III efficacy studies.
Methods
The two trials were randomised, double-blind, placebo-
controlled multiple-dose studies in healthy post-menopausal
female volunteers aged between 45 and 62 years (inclusive).
Both trials had the same entry criteria and were of similar
design.
In the first study (trial 1), a total of eight volunteers were
given eight doses of 3 mg of ZD1033 over 10 days to assess
tolerability, pharmacokinetics and effects on endocrinology.
In the second study (trial 2) a total of 14 volunteers were
given 0.5 and 1 mg doses of ZD1033 daily for 14 days to
assess the tolerability, pharmacokinetics and effect on serum
oestradiol concentrations only.
Post-menopausal status of the volunteers was defined as
CN
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no menstrual periods for the previous 12 months and a serum
concentration of follicle-stimulating hormone (FSH) consis-
tent with menopause (31 - 134 IU 1-l).
The key inclusion criteria were: at least one intact ovary;
cervical smear negative for malignancy within the previous 12
months; normal clinical laboratory parameters and; normal
clinical examination. Key exclusion criteria were a history of
malignant breast disease or previous hysterectomy as a result
of malignancy.
Vital signs, including electrocardiogram (ECG) and 24 h
continuous ambulatory ECG, symptoms and clinical
laboratory assessments were conducted at various times to
monitor the clinical safety of the volunteers.
Trial I
A total of eight volunteers received eight doses of 3 mg of
ZD1033 and seven volunteers received eight doses of
matching placebo given over two 10 day periods separated
by 14 days (one volunteer withdrew for non-medical reasons
unrelated to the trial after she had completed the first
treatment period and did not receive placebo). On the second
and third study day of each treatment period no dose of
ZD1033 or placebo was given so that the 72 h pharmacoki-
netic profile of a single dose of 3 mg of ZD1033 could be
established. A dose of 3 mg ZD1033 or matching placebo
was then given on the following 7 consecutive days (study
days 4-10).
Blood samples for measurement of plasma ZD1033 were
collected pre-dose and at selected times up to 72 h after the
first dose on study day 1 and the last dose on study day 10,
with an additional sample taken 96 h after the last dose.
Blood samples for assay of serum oestrone, oestradiol and
androstenedione were collected before dosing and at times up
to 72 h after dosing on study day 1, pre-dosing on study days
6, 8 and 10 and at selected times up to 96 h after dosing on
study day 10.
Samples for assay of serum aldosterone, cortisol, 17-
hydroxyprogesterone (17-HP), dehydroepiandrosterone sul-
phate (DHEA-S), luteinising hormone (LH), FSH and
adrenocorticotrophic hormone (ACTH) were collected
before and 3 h after dosing on study days 1 and 10 of both
treatment periods. Additional samples for cortisol assay were
also collected before dosing on study days 3, 5, 7 and 9 in
both treatment periods.
An ACTH stimulation test was performed 3 h after the
dose on study day 10. Blood samples were collected at 30 min
and 60 min after synacthen (ACTH) injection (250 mg
intramuscularly) for measurements of cortisol, 17-HP and
DHEA-S.
Trial 2
Seven volunteers per treatment group received 14 consecutive
daily doses of either 0.5 mg or 1 mg of ZD1033. Blood was
collected for determination of plasma ZD1033 and serum
oestradiol at various times during the study, namely before
dosing and selected times up to 12 h after dosing on study
day 1, pre-dose on study days 2-14 and up to 144 h after
dosing on study day 14.
All plasma samples for ZD1033 analyses were stored at
-70°C and analysed by the Drug Kinetics and Metabolism
Group, Zeneca Pharmaceuticals, Wilmington, DE, USA,
using a validated method employing solvent extraction,
capillary gas chromatography (GC) separation with electron
capture detection (ECD).
Serum oestrone, oestradiol and androstenedione assays
were conducted using validated methodology (Harris et al.,
1983; Dowsett et al., 1987) at The Royal Marsden Hospital,
Fulham Road, London, UK. The assay for serum oestradiol
had a limit of detection of 3 pmol 1-'.
Clinical chemistry, haematology, urinalysis and other
hormone assays were analysed at the Central Laboratory,
Zeneca Pharmaceuticals, Macclesfield, UK.
The two trials described were approved by the Indepen-
dent Ethics Committee of Inveresk Research International,
Edinburgh.
Analysis of data
Hormone data
Owing to the variability of oestradiol concentrations between
individuals oestradiol values were scaled to baseline: base-line
scaled (BS) values were obtained by dividing post-dose values
by corresponding pre-dose values.
Any oestradiol values falling below the limit of quantifica-
tions were substituted by the value assigned as the limit of
quantification.
Oestrogen data from the first study were scaled to baseline
and summarised by geometric mean (BS mean). The per cent
reduction of the BS mean after dosing with ZD1033 was
calculated relative to the BS mean for placebo at the
corresponding time point.
The BS mean concentrations of the other hormones
assessed, including the cortisol and 17-HP response to
ACTH stimulation were analysed using hormone data from
study 1. Analysis of variance was used allowing for the effect
of volunteers, time and treatments. Estimates of treatment
effects were calculated together with 95% confidence limits
and statistical significance.
Using data from the second study the area under the BS
oestradiol concentration-time curve (AUC) after dosing with
0.5 and 1.0 mg of ZD1033 was analysed using analysis of
variance. BS values at 24 h after dosing on study days 1, 2, 3,
5, 7, 13 and 14 were used to define the AUC. These values
were normalised by dividing AUC by time period.
Pharmacokinetic data
The terminal elimination rate constant for ZD1033 was
obtained using data from both studies by linear regression
analysis of the natural logarithm of plasma ZD1033
concentrations obtained during the terminal elimination
phase at the respective times. The terminal elimination half-
life was calculated by dividing 0.693 by the elimination rate
constant.
Using data from the first study, the maximum plasma
concentration (Cm,) and the time of Cmax (tmax[) after dosing
with 3 mg of ZD1033 were determined on study days 1 and
10. AUC (0-24) was calculated using the trapezoidal rule
and AUC (0-oo) was calculated by extrapolation using the
terminal rate constant. The maximum, minimum and mean
concentrations on day 10 were determined. Comparison of
day 1 AUC (0-oo) with day 10 AUC (0-24) was used to
determine ifsteady state had been reached. The ratio ofAUC
(0-24) on study day 10 to AUC (0-Xc) on study day 1 was
calculated from the plasma concentration data and used to
assess accumulation. A log transformation was performed on
the ratios and analysed using a one-sided t-test.
The change in half-life from study day 1 to study day 10
after dosing with 3 mg of ZD1033 was analysed using a
paired t-test.
In the second trial, Cma. and tmax after dosing with either
0.5 or 1.0 mg of ZD1033 were determined on study day 1.
Minimum, maximum and mean Cmax values were calculated
as were minimum, maximum and median tmax values. Ratios
of minimum plasma concentrations (Ci,,,) on study days 5-
14 relative to Cmin on study day 8 (Cmi. 8) were calculated.
The statistical analyses were carried out using the SAS
package (SAS Institute, Cary, NC, USA).
Results
Oestrogen concentrations
After the first dose of 3 mg of ZD1033, mean serum
oestradiol concentrations progressively decreased, being
reduced by approximately 70% compared with placebo by48 h (P =0.001), with no recovery apparent by 72 h when
dosing was resumed. On continued dosing from days 4-10,
oestradiol concentrations further decreased to approximately
80% compared with placebo values (P=0.004) by day 8
(Figure 2), remaining at that level until 24 h after the last
dose, when oestradiol concentrations were still suppressed by
70% compared with placebo values. All mean serum
oestradiol concentrations (except those 6 h after the first
dose and 72 and 96 h after the last dose) were statistically
significantly different from the corresponding placebo values.
Some variation in oestradiol concentrations was evident;
however, this is largely owing to the low concentrations being
measured and was not considered clinically significant.
The apparent increase in mean oestradiol concentrations
observable 24 h after the first dose of placebo (Figure 2) was
attributed to two out of seven volunteers having increased
oestradiol concentrations at this time point; furthermore, the
apparent decrease in mean serum oestradiol concentrations
observable on day 13 in the placebo group was owing to one
out of seven of the volunteers exhibiting a low oestradiol
concentration (c. 3.5 pmol 1-l) at this time point. The
variation in mean oestradiol concentrations in the placebo
group throughout the trial were considered to be within the
normal limits of biological variation in post-menopausal
women.
A similar overall pattern of decreases was also seen in
mean serum oestrone concentrations following dosing with
3 mg of ZD1033. Maximal suppression of approximately
40% compared with placebo values was recorded from study
day 6 onwards with no recovery apparent by 96 h after the
last dose (Table I).
In trial 2, all volunteers completed the trial but data from
one volunteer in the 0.5 mg group were excluded from
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endocrine analysis because her oestradiol concentrations
indicated that she was not post-menopausal. One further
volunteer in this dose group had an initial pre-dose oestradiol
level greater than all the others, resulting in the mean initial
values for this group appearing to be higher than the 1 mg
group.
On treatment with 0.5 and 1 mg of ZD1033, mean
oestradiol concentrations decreased after the first dose and
remained suppressed from 3 h after the first dose to 6 days
after the last dose. Mean post-dose scaled oestradiol
concentrations were suppressed by 84% and 86% compared
with baseline values in the 0.5 and 1.0 mg groups
respectively. Mean scaled oestradiol AUC 24 h after dosing
on days 1-14 showed reductions of 82% and 84% for the
0.5 and 1.0 mg groups respectively.
Mean oestradiol concentrations are shown in Figure 3,
Table II summarises the analysis of the mean baseline-scaled
oestradiol concentration 24 h after the 13th and 14th dose
and analysis of oestradiol AUC following dose 1 to dose 14.
These analyses showed no statistically significant differ-
ences between the 0.5 and 1 mg doses. However, 24 h after
the last dose of ZD1033, serum oestradiol concentrations
were below the limit of detection of the assay in the majority
(five out of seven) of women receiving 1 mg of ZD1033 daily
compared with one out of six women receiving 0.5 mg of
ZD1033 daily, even though in the majority of cases pre-dose
oestradiol levels on day 1 were similar in both dose groups.
Oestradiol concentrations fell from baseline mean values of
46 pmol l` and 28 pmol 1-1 to mean post last dose values of
5.9 pmol 1-1 and 3.2 pmol I' in the 0.5 mg and the 1.0 mg
groups respectively.
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Figure 2 Mean oestradiol levels (+s.d.) with 3mg of ZD1033
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Figure 3 Mean oestradiol levels (±s.d.) with 0.5mg and 1mg of
ZD1033 daily. A, 0.5mg at n=6; l, 1.0mg at n=7. +Six hours
after dose day 1. *Twelve hours after dose day 1.
Table I Scaled oestrone: percent reduction in geometric mean after 3 mg of ZD1033 relative to placebo
96 h after dose
Day 2 Day 3 Day 4 Day 6 Day 8 Day 10 on day 10
Percentage reduction 36.2 29.4 34.6 41.1 34.8 44.9 39.7
Table II Statistical analysis of oestradiol concentrations: BS oestradiol AUC 1 - 14 days and mean BS oestradiol concentrations 24 h after
dosing on days 13 and 14
0.5 mg of 1.0 mg of
ZD1033 ZD1033 Mean post-dose oestradiol suppression
Adjusted geo- Adjusted geo- Treatment effect 95% 0.5 mg of I mg of
n metric means n metric means (ratio 0.5 - 1.0 mg) confidence P-value ZD1033 ZD1033
AUC days 1 - 14 7 0.175 6 0.160 1.09 (0.52, 2.30) 0.794 82% 84%
Mean days 13 and 14 7 0.156 6 0.138 1.13 (0.55, 2.33) 0.713 84% 86%
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Other steroid hormones
No statistically significant changes occurred in mean serum
concentration of cortisol, with values after dosing with 3 mg
of ZD1033 being almost identical to those obtained on
placebo at most points.
Similarly, no consistent changes in mean serum concentra-
tions of aldosterone, 17-HP or androstenedione occurred
during treatment with ZD1033. None were statistically
significant.
No clinically significant alterations in mean serum
concentrations of DHEA-S after dosing with 3 mg of
ZD1033 relative to placebo were recorded during the trial.
ACTH stimulation test
In volunteers receiving 3 mg of ZD1033, the mean cortisol
and 17-HP responses 30 and 60 min following ACTH
stimulation were similar to those receiving placebo (Figure 4).
No clinically or statistically significant differences in
response to ACTH stimulation were recorded; numerical
values for both cortisol and 17-HP after ACTH stimulation
from volunteers dosed with ZD1033 were within 12% of
those obtained on placebo.
Pituitary hormones
None of the data suggested an effect of ZD1033 on ACTH,
LH or FSH.
The majority of values for ACTH fell below the limit of
detection of the assay and only limited observations were
possible.
ACTH was measurable in only four out of eight
volunteers after both ZD1033 and placebo. In three of these
volunteers the ACTH concentrations after ZD1033 were
lower than the corresponding placebo values; in one
volunteer they were higher, but all concentrations remained
within the reference range.
Mean serum LH and FSH concentrations were virtually
identical to the corresponding placebo values 3 h after the first
dose, and before and 3 h after the last 3 mg dose ofZD1033.
Table III shows the analysis of the scaled geometric mean
of a range of hormones from days 1 and 10 after dosing with
3 mg of ZD1033.
Pharmacokinetics
Mean plasma ZD1033 concentrations after dosing with
3.0 mg of ZD1033 increased following multiple dosing;
plasma concentrations at steady state were approximately
3.5 times greater than after a single dose of 3.0 mg of
ZD1033. (Figure 5).
Mean Cmax values after the first dose of 0.5 and 1.0 mg of
ZD1033 were 5.97 ng ml-1 and 13.7 ng ml-' respectively.
Mean plasma ZD1033 concentrations after the 1.0 mg dose
were approximately twice those obtained after the 0.5 mg
dose. (Figure 6).
Cmax occurred at 2- 12 h after dosing for all three doses of
ZD1033. The median tmax for 3 mg of ZD1033 was 3 h on
both study days 1 and 10, whereas for the 0.5 and 1.0 mg
doses the median tmax was 2 h.
Mean half-life values obtained after the first and last doses
of 3 mg of ZD1033 were 50.7 and 45.4 h respectively, the
difference in half-life between the first and last doses was not
statistically significant. For the 0.5 and 1.0 mg doses of
ZD1033 the mean half-lives were determined to be 45.7 and
40.6 respectively.
Comparison of Cmin values after dosing with 0.5 or 1.0 mg
ZD1033 on study days 5-15 indicated that steady state
concentrations were reached by day 9.
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Figure 4 Scaled cortisol following ACTH stimulation and
multiple (eight) daily dosing with 3mg of ZD1033 in healthy
post-menopausal volunteers. A, 3mg of ZD1033; C1, placebo.
Figure 5 Plasma concentrations of ZD1033 on days 1 and 10
following daily dosing with 3mg of ZD1033: geometric mean
value. M, day 1; *, day 10.
Table III Changes (%) scaled geometric mean of a range of hormones after 3 mg of ZD1033 relative to placebo
Day 1 Day 10
3 h after dose Pre-dose 3 h after dose
Percentage 95% confidence Percentage 95% confidence Percentage 95% confidence
change limit P-value change limit P-value change limit P-value
Scaled -12.9 (-61.34, 96.06) 0.679 24.6 (-42.45, 169.85) 0.497 21.0 (-41.72, 151.31) 0.532
aldosterone
Scaled -26.9 (-63.6, 46.66) 0.299 3.8 (-52.98, 129.33) 0.908 48.9 (-36.78, 250.53) 0.286
17-HP
Scaled LH -9.5 (-22.81, 6.03) 0.166 -9.3 (-24.76, 9.34) 0.237 12.2 (-19.04, 55.35) 0.407
Scaled FSH 0.01 (-5.94, 6.34) 0.995 1.54 (-13.06, 18.58) 0.810 -3.4 (-24.49, 23.52) 0.731
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Figure 6 Mean plasma concentrations of ZD1033 (ng,±s.e.);
profile for 24h following dosing on day 1 with 0.5 ( ) or
1.0mg (----) of ZD1033.
Tolerability
ZD1033 was well tolerated in post-menopausal female
volunteers and there were no serious adverse events recorded
after multiple dosing with ZD1033. There was no obvious
excess ofvolunteers experiencing minor adverse events during
ZD1033 treatment compared with placebo.
The few individual occurrences of haematology, clinical
chemistry or urinalysis variables found to be outside relevant
reference ranges were not considered to be drug-related
effects and were found inconsistently before and after dosing
with ZD1033 and placebo. There was no evidence of changes
in blood pressure, pulse rate or ECG related to ZD1033.
Discussion
The reductions in serum concentrations of oestradiol and
oestrone confirm that ZD1033 is a potent aromatase inhibitor
in post-menopausal women.
Based on these results from the second trial, the 1 mg dose
of ZD1033 was selected as the low dose to be further
investigated in a multicentre comparison with megestrol
acetate.
Although the serum ACTH data were limited by the
number of samples falling below the detection limit of the
assay, it appears that no significant rise in serum ACTH
concentration occurred on dosing with ZD1033.
There were no significant changes in cortisol, aldosterone,
17-HP or androstenedione concentrations after seven
consecutive doses and steroid response to standard ACTH
challenge was unimpaired by ZD1033. These data demon-
strate ZD1033 to be a highly selective aromatase inhibitor
that does not disturb any of the major pathways of adrenal
steroidogenesis.
The absence of any detectable changes in LH and FSH
concentrations is evidence that ZD1033 does not possess
oestrogenic, progestational or androgenic activity and does
not affect gonadotrophin release by any other mechanism in
post-menopausal women. The absence of increases in these
hormones is in accordance with the post-menopausal status
of the volunteers in whom negative feedback by ovarian
hormones would have been inoperative for at least 12
months.
There are currently two aromatase inhibitors (aminoglu-
tethimide and formestane) licensed for the treatment of
advanced breast cancer in post-menopausal women. Amino-
glutethimide has been in use as a breast cancer treatment
since 1981, however, it is associated with marked toxicity and
at the conventional dose of 250 mg q.i.d., it is non-selective
for the aromatase enzyme, also inhibiting adrenal gland
steroidogenesis, thus necessitating co-administration with
glucocorticoids (Lonning and Johannessen, 1991). Formes-
tane, a steroidal 'suicide inhibitor' was launched in 1992;
formestane is given as a 250 mg i.m. dose once every 2 weeks,
and at this dose level leads to oestradiol suppression of 49-
64% (Stein et al., 1990) but is associated with injection site
reactions (Hoffken et al., 1993).
There are at present a number of aromatase inhibitors in
earlier stages of clinical development (Goss and Gwynn,
1994) than Arimidex (ZD1033). Letrozole (CGS 20267),
fadrozole (CGS 16949A) and vorozole (R83842) are cur-
rently being assessed in phase III comparative studies.
Prerequisites of a new generation aromatase inhibitor are
that it should:
(1) be selective for the aromatase enzyme;
(2) be potent and highly effective at reducing serum
oestrogen levels;
(3) be convenient and easy to administer;
(4) lack significant toxicology.
The two studies described in this publication have shown
that Arimidex, when given once daily p.o., is highly potent at
reducing serum oestradiol levels [to the limit of detection of
the available assay (>80%) at 1 mg daily], while having no
effect upon adrenal gland steroidogenesis.
A greater than 80% reduction in oestradiol levels with
Arimidex compares with a 67-78% reduction with fadrozole
(Santen et al., 1991) and reductions of 89-91% and up to
86% with vorozole (Johnston et al., 1994) and letrozole
(Iveson et al., 1993) respectively, indicating a similar level of
effect with all four drugs.
When selectivity of action is considered, it is well known
that fadrozole interferes with cortisol and aldosterone
synthesis at doses of 0.6 mg t.i.d.-2 mg b.i.d. (Santen et
al., 1991; Demers et al., 1993). A recent publication reported
that vorozole 5 mg daily led to a small reduction in serum
cortisol following 28 daily doses (Johnston et al., 1994). The
authors of this conclude that the relevance of this finding was
unclear and of doubtful clinical significance. There have been
no reports of letrozole interfering with adrenal steroidogen-
esis.
Overall these data show that ZD1033 is a well-tolerated,
potent and selective aromatase inhibitor without discernible
effect on those enzymes that regulate adrenocorticoid
biosynthesis. ZD1033 is of at least similar pharmacological
effectiveness as other aromatase inhibitors in clinical
development.
Data from these studies strongly suggest that Arimidex
has the potential to be clinically effective in the control of
breast cancer by virtue of its potent aromatase inhibition.
Furthermore its selectivity suggests it will be free of side-
effects associated with other less selective compounds.
Additionally, the pharmacokinetic profile of ZD1033 sup-
ports its use as a once-daily treatment given by the oral
route.
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